The Journal of clinical endocrinology and metabolism
-
J. Clin. Endocrinol. Metab. · Apr 2020
Randomized Controlled Trial Clinical TrialSotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
The effect of sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans. ⋯ Sotagliflozin delayed and blunted intestinal glucose absorption after meals, resulting in lower PPG and insulin levels, likely due to prolonged local inhibition of intestinal SGLT1 that persisted for ≥5 hours after dosing.
-
J. Clin. Endocrinol. Metab. · Apr 2020
Pragmatic Clinical TrialEffect of Salt Supplementation on Sympathetic Activity and Endothelial Function in Salt-Sensitive Type 2 Diabetes.
Lower sodium intake is paradoxically associated with higher mortality in type 2 diabetes (T2D). ⋯ In people with T2D and low habitual sodium intake, salt supplementation increased SNS activity without altering endothelial function or blood pressure but improved baroreflex function, a predictor of cardiac mortality. Salt-resistant individuals trended toward improved endothelial function with salt supplementation.